MEDISYSTEMS CORPORATION – Trademark Portfolio
Entity Type: 03
MEDISYSTEMS CORPORATION holds 41 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 30 filings in this category. The portfolio also extends into Class 41 (Education & Entertainment) across 3 Nice Classification classes. Currently, 7 trademarks are registered. Notable registered marks include REVERSO, LOCKSITE, STERIPICK, TWINPACK+, and BUTTONHOLE. The owner is based in San Francisco, CA.
345 California Street, 21st Floor
San Francisco, CA 94104
Showing of trademarks Trademarks
Trademark Classifications
MEDISYSTEMS CORPORATION's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Education; providing of training; entertainment; sporting and cultural activities
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does MEDISYSTEMS CORPORATION have?
MEDISYSTEMS CORPORATION has 41 U.S. trademarks filed with the USPTO. Of these, 7 registered, 20 abandoned, 14 cancelled.
What trademark classes does MEDISYSTEMS CORPORATION file in?
MEDISYSTEMS CORPORATION files trademarks across 3 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 41 (Education & Entertainment), Class 5 (Pharmaceuticals). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are MEDISYSTEMS CORPORATION's most well-known trademarks?
MEDISYSTEMS CORPORATION's registered trademark portfolio includes well-known marks such as REVERSO, LOCKSITE, STERIPICK, TWINPACK+, and BUTTONHOLE. These are among 7 currently registered trademarks in the portfolio.
What is MEDISYSTEMS CORPORATION's trademark registration success rate?
MEDISYSTEMS CORPORATION has a 17% trademark registration rate, with 7 out of 41 resolved applications resulting in successful registration. Currently, 0 applications are pending review.